The Importance of Poly(ethylene glycol) Alternatives for Overcoming PEG Immunogenicity in Drug Delivery and Bioconjugation
Open accessThe DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
Abstract
Poly(ethylene glycol) (PEG) is widely used as a gold standard in bioconjugation and nanomedicine to prolong blood circulation time and improve drug efficacy. The conjugation of PEG to proteins, peptides, oligonucleotides (DNA, small interfering RNA (siRNA), microRNA (miRNA)) and nanoparticles is a well-established technique known as PEGylation, with PEGylated products have been using in clinics for the last few decades. However, it is increasingly recognized that treating patients with PEGylated drugs can lead to the formation of antibodies that specifically recognize and bind to PEG (i.e., anti-PEG antibodies). Anti-PEG antibodies are also found in patients who have never been treated with PEGylated drugs but have consumed products containing PEG. Consequently, treating patients who have acquired anti-PEG antibodies with PEGylated drugs results in accelerated blood clearance, low drug efficacy, hypersensitivity, and, in some cases, life-threatening side effects. In this succinct review, we collate recent literature to draw the attention of polymer chemists to the issue of PEG immunogenicity in drug delivery and bioconjugation, thereby highlighting the importance of developing alternative polymers to replace PEG. Several promising yet imperfect alternatives to PEG are also discussed. To achieve asatisfactory alternative, further joint efforts of polymer chemists and scientists in related fields are urgently needed to design, synthesize and evaluate new alternatives to PEG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Anti-PEG IgM production as a function of time interval was tested in sera of rats intravenously injected with PEGylated liposomal gambogenic acid (PEG-GEA-L) at 1.500 mg/kg (a) [57]. Mice were treated with PEGylated liposomes of 1 μmol/kg, and the production of anti-PEG IgM in mouse sera was determined as a function of time (b) [58]. The effect of PEG-GEA-L doses on anti-PEG IgM production was recorded on the fifth day after the first injection. Rats were treated with low (1.125 mg/kg), medium (1.500 mg/kg), and high (1.875 mg/kg) dosages. ELISA was utilized to determine anti-PEG IgM (c). Anti-PEG IgM in organ tissues of rats that were intravenously injected with various PEG-GEA-L doses (d). Used with permission from [57]. (* p < 0.05, ** p < 0.01).](https://figures.cochat.ai/paper-figures/7f992d6c8db34717873a1a30c4da9e3e/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-3.jpg)
![Figure 4 Production of anti-PEG IgM in the serum of mice injected PEGylated liposomes (PL) with various functional groups were determined by ELISA on the fifth day after administration. The lowest immunogenicity was exhibited by PL–OH (a). C3 binding in the serum of mice injected P–OCH3 and PL–OH on the fifth day, with non-treated mice as the control sample. Sera were diluted with a gelatin veronal buffer with Mg++ and Ca++ (GVB++) buffer (b) and an Mg2+/ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA) buffer (c). Mice treated with PL–OH demonstrated the highest compliment activation, driving the ABC phenomenon (d). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [65]. Production of anti-PEG IgM rat sera against PEGylated emulsions (DE) with various functional groups seven days post-administration (e). Used with permission from the European Journal of Pharmaceutics and Biopharmaceutics [66]. (* p < 0.05, ** p < 0.01, *** p < 0.001).](https://figures.cochat.ai/paper-figures/334fab17dd8d42068469652d228b7ccc/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-4.jpg)



![Figure 8 Chemical structure of the zwitterionic carboxybetaine functionalized polypeptide (PepCB) [79] (a). The preparation of poly(2-methacryloyloxyethyl phosphorylcholine)/poly(β-amino ester) (PMPC/PAE) mixed shell micelles (MSMs) with pH-sensitive behavior: MSMs were in zwitterionic state at a physiological blood pH (7.4) and in a cationic form within the tumor microenvironment (pH 6.5) (b).](https://figures.cochat.ai/paper-figures/52e563c21690478d8f338572002a504f/the-importance-of-poly-ethylene-glycol-alternatives-for-overcoming-peg-figure-8.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, these chemical modifications can potentially decrease transduction efficiency, lower production yield, alter biodistribution of AAV vectors, and result in anti-polymer antibody formation [198, 199].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [199]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533 · cited 3×
“However, the repeated administration of these polymers and/or NP-polymer conjugates may still trigger the production of anti-polymer antibodies, and further studies are needed to fully elucidate their immunogenic profiles [75,76].”
BackgroundPEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Jiang, S., & Cao, Z. (2010) · Advanced Materials · doi:10.1002/adma.200901407 · Cited by 2,027 · cited 4×
“Synthetic zwitterionic materials such as poly(carboxybetaine) (pCB) and poly(sulfobetaine) (pSB) (Figure 7) have been proposed as PEG alternatives due to their strong hydration, conferring high resistance to nonspecific protein fouling in addition to their inherently low immunogenicity [77,78].”
BackgroundInfluentialChemistry for peptide and protein PEGylation
Roberts, M. J., Bentley, M. D., & Harris, J. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00022-4 · Cited by 1,604
Polyethylene glycol (PEG): A versatile polymer for pharmaceutical applications
D’souza, A. A., & Shegokar, R. (2016) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1182485 · Cited by 1,282
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage
Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721
Bertrand, N., Grenier, P., Mahmoudi, M., Lima, E. M., Appel, E. A., Dormont, F., Lim, J.-M., Karnik, R., Langer, R., & Farokhzad, O. C. (2017) · Nature Communications · doi:10.1038/s41467-017-00600-w · Cited by 708 · cited 3×
“When considering continuously increasing PEG density, it was shown that high PEG densities did not significantly impact NP clearance from circulation [59], though discussion of the relationship between clearance and anti-PEG IgM production, as a known causative factor of ABC, was omitted [37].”
Background
Research works printed but not linked: 4
- 23. Mukhopadhyay S. Nano drugs: A critical review of their patents and market. In: Mohapatra S.S., Ranjan S., Dasgupta N., Mishra R.K., Thomas S., editors. Characterization and Biology of Nanomaterials for Drug Delivery: Nanoscience and Nanotechnology in Drug Delivery. Elsevier Ltd.; Amsterdam, The Netherlands: 2019. pp. 523–551.
- 39. Elsadek N.E., Abu Lila A.S., Ishida T. 5-Immunological responses to PEGylated proteins: Anti-PEG antibodies. In: Pasut G., Zalipsky S., editors. Polymer-Protein Conjugates. Elsevier; Amsterdam, The Netherlands: 2020. pp. 103–123.
- 47. Seppälä J.T.S., Mäkelä O. Hapten. In: Roitt I., Delves P., editors. Encyclopedia of Immunology. 2nd ed. Elsevier Ltd.; Amsterdam, The Netherlands: 1998. pp. 1050–1052.
- 72. Abbina S., Parambath A. PEGylation and its alternatives: A summary. In: Parambath A., editor. Engineering of Biomaterials for Drug Delivery Systems: Beyond Polyethylene Glycol. Elsevier Ltd.; Amsterdam, The Netherlands: 2018. pp. 363–376.
Cited by
Items 101–200 of 669
Berger, M., Toussaint, F., Djemaa, S. B., Laloy, J., Pendeville, H., Évrard, B., Jérôme, C., Lechanteur, A., Mottet, D., Debuigne, A., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.031 · Cited by 63
Analysis of multi-drug cancer nanomedicine
Benderski, K., Lammers, T., & Sofias, A. M. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01932-1 · Cited by 73
Abesekara, M. S., & Chau, Y. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.972790 · Cited by 61
Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles
O’Brien, M. N., Foley, D. A., Pak, R. H., Lewis, J. A., McKinney, E., Egan, P. M., Yerabolu, R., Dane, E. L., Dirat, O., Gorka, L. S., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-024-01833-9 · Cited by 67
Materials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 59
Manivasagan, P., Kim, J., & Jang, E. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214701 · Cited by 55
Engineered Liposomes in Interventional Theranostics of Solid Tumors
Kommineni, N., Chaudhari, R., Conde, J., Tamburacı, S., Çeçen, B., Chandra, P., & Prasad, R. (2023) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.3c00510 · Cited by 58
Engineered therapeutic proteins for sustained-release drug delivery systems
Nguyen, T. T. K., Pham, K., & Yook, S. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.09.018 · Cited by 60
Nanomaterial-based drug delivery systems as promising carriers for patients with COVID-19
Elkodous, M. A., Olojede, S. O., Morsi, M., & El-Sayyad, G. S. (2021) · RSC Advances · doi:10.1039/d1ra04835j · Cited by 56
Humoral immune responses to AAV gene therapy in the ocular compartment
Whitehead, M., Osborne, A., Yu‐Wai‐Man, P., & Martin, K. (2021) · Biological Reviews · doi:10.1111/brv.12718 · Cited by 52
Andrade, R. G. D., Reis, B., Costas, B., Lima, S. A. C., & Reis, S. (2020) · Polymers · doi:10.3390/polym13010088 · Cited by 58
Sequence- and stereo-defined macromolecules: Properties and emerging functionalities
Szweda, R. (2023) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2023.101737 · Cited by 52
Oral administration microrobots for drug delivery
Ren, A., Hu, J., Qin, C., Xia, N., Yu, M., Xu, X., Yang, H., Han, M. Y., Zhang, L., & Ma, L. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.05.005 · Cited by 75
“Till now, PEG and PEG-conjugated drugs have been approved by FDA for human [53].”
BackgroundDevelopment of Polymer-Assisted Nanoparticles and Nanogels for Cancer Therapy: An Update
Neerooa, B. N. H. M., Ooi, L.-T., Shameli, K., Dahlan, N. A., Islam, J. M. M., Pushpamalar, J., & Teow, S. (2021) · Gels · doi:10.3390/gels7020060 · Cited by 55
“PEG-based NPs are intrinsically less toxic with the ability to reduce cytotoxicity of cationic polymers to shorten renal clearance, thereby extends circulation time in blood [97].”
BackgroundCraft of Co-encapsulation in Nanomedicine: A Struggle To Achieve Synergy through Reciprocity
Bhattacharjee, S. (2022) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00033 · Cited by 54
Nanoformulations for Delivery of Pentacyclic Triterpenoids in Anticancer Therapies
Kaps, A., Gwiazdoń, P., & Chodurek, E. (2021) · Molecules · doi:10.3390/molecules26061764 · Cited by 52
“, difficult interactions with host cells and cellular uptake, excessive accumulation, and even the formation of anti-PEG antibodies [51].”
BackgroundMolecular engineering of antimicrobial peptide (AMP)–polymer conjugates
Cui, Z., Luo, Q., Bannon, M. S., Gray, V. P., Bloom, T. G., Clore, M. F., Hughes, M. A., Crawford, M. A., & Letteri, R. A. (2021) · Biomaterials Science · doi:10.1039/d1bm00423a · Cited by 56
Advances in lipid nanoparticle mRNA therapeutics beyond COVID-19 vaccines
Wu, Y., Yu, S., & de Lázaro, I. (2024) · Nanoscale · doi:10.1039/d4nr00019f · Cited by 57
Nanocarrier-Based Delivery Systems for Natural Compounds Across Research Stages
Antonelli, A., & Palma, F. (2025) · Materials · doi:10.3390/ma18214960 · Cited by 60
“These immune responses, associated with the accelerated blood clearance (ABC) phenomenon and limited PEG biodegradability, can compromise long-term efficacy and cause hepatic or lysosomal accumulation [32–35].”
Lacombe, J., Harris, A. F., Zenhausern, R., Karsunsky, S., & Zenhausern, F. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00932 · Cited by 53
Kabil, M. F., Azzazy, H. M. E.-S., & Nasr, M. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.123871 · Cited by 60
Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment—A Recent Review
Arafat, M., Sakkal, M., Beiram, R., & Aburuz, S. (2024) · Pharmaceuticals · doi:10.3390/ph17030315 · Cited by 56
“These techniques include the use of PEGylated nanoparticles, which involve attaching PEG to the surface of nanoparticles to enhance their circulation time and reduce RES clearance [141].”
MethodPolymer-mediated protein/peptide therapeutic stabilization: Current progress and future directions
Sivasankaran, R. P., Snell, K., Kunkel, G. E., Georgiou, P. G., Puente, E. G., & Maynard, H. D. (2024) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2024.101867 · Cited by 57
Trapani, A., Guerra, L., Corbo, F., Castellani, S., Sanna, E., Capobianco, L., Monteduro, A. G., Manno, D. E., Mandracchia, D., Gioia, S. D., et al. (2021) · Molecules · doi:10.3390/molecules26040916 · Cited by 54
“However, recent data have indicated the occurrence of immunogenic responses against PEG, resulting in hypersensitivity reactions and lack of therapeutic efficacy of the administered drug [58,59].”
BackgroundShin, K., Suh, H., Grundler, J., Lynn, A. Y., Pothupitiya, J. U., Moscato, Z. M., Reschke, M., Bracaglia, L. G., Piotrowski-Daspit, A. S., & Saltzman, W. M. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121676 · Cited by 50
Building Blocks to Design Liposomal Delivery Systems
Juszkiewicz, K., Sikorski, A. F., & Czogalla, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249559 · Cited by 52
“Some hydrophilic polymers (such as polyglycerols and polyoxazolines) and zwitterionic polymers have shown a comparable or improved results in producing stealth formulations [121].”
BackgroundNguyen, D. H., Vo, T. N. N., Nguyen, N. T., Ching, Y. C., & Thi, T. T. H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239360 · Cited by 47
“The same situation also occurred for other synthetic polymers [30], so they should be not considered in surface modification.”
BackgroundSelf-citationMa, Z., Wong, S. W., Forgham, H., Esser, L., Lai, M., Leiske, M. N., Kempe, K., Sharbeen, G., Youkhana, J., Mansfeld, F. M., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121539 · Cited by 48
Ebadi, M., Zain, A. R. M., Aziz, T. H. T. A., Mohammadi, H., Tee, C. A. T., & Yusop, M. R. (2023) · Polymers · doi:10.3390/polym15040971 · Cited by 49
Polyplex designs for improving the stability and safety of RNA therapeutics
Uchida, S., Lau, C. Y. J., Oba, M., & Miyata, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114972 · Cited by 52
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Nanoscale delivery platforms for RNA therapeutics: Challenges and the current state of the art
Rhym, L. H., & Anderson, D. G. (2022) · Med · doi:10.1016/j.medj.2022.02.001 · Cited by 49
Exploring the role of polymers to overcome ongoing challenges in the field of extracellular vesicles
Simon, L., Lapinte, V., & Morille, M. (2023) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12386 · Cited by 49
“In recent reviews, categories and characteristics of six PEG alternatives including as polyesters, poly(oxazolines) or polyacrylamides were discussed (Hoang Thi et al., 2020; Knop et al., 2010; Yao et al., 2023).”
BackgroundPLGA nanoparticles for nasal drug delivery
Alghareeb, S., Asare‐Addo, K., Conway, B. R., & Adebisi, A. O. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105564 · Cited by 56
Balancing stealth and targeting to improve nanomedicine efficacy
Ju, Y., & Kent, S. J. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-01926-z · Cited by 50
Ibarra-Sánchez, L. Á., Gámez-Méndez, A. M., Martínez-Ruiz, M., Nájera-Martínez, E. F., Morales-Flores, B., Melchor-Martínez, E. M., Sosa‐Hernández, J. E., Parra‐Saldívar, R., & Iqbal, H. M. N. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103219 · Cited by 49
Rele, S. S. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1822136 · Cited by 48
“conjugated lipid in mRNA-LNP formulations to stimulate antiPEG response in prophylactic mRNA-LNP vaccines and its role in induction of accelerated blood clearance (ABC) will need more clarity.(10) It also remains unclear if the sourcing supply chain partners can meet the demand and supply of high quality and controlle…”
BackgroundRecent Advances of Emerging Spleen‐Targeting Nanovaccines for Immunotherapy
He, X., Wang, J., Tang, Y., Chiang, S. T., Han, T., Chen, Q., Qian, C., Shen, X., Li, R., & Ai, X. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300351 · Cited by 51
Le, N. T. T., Nguyen, D. T. D., Nguyen, N. H., Nguyen, C. K., & Nguyen, D. H. (2020) · Journal of Applied Polymer Science · doi:10.1002/app.49858 · Cited by 44
Self-citationTavares, G., Alves, P., & Simões, P. N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071377 · Cited by 43
Effects of PEG antibodies on in vivo performance of LNP-mRNA vaccines
Yang, M. J., Zhang, Z., Jin, P., Jiang, K., Xu, Y., Pan, F., Tian, K., Yuan, Z., Liu, X., Fu, J., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123695 · Cited by 46
Protein-based nanoparticles for therapeutic nucleic acid delivery
Eweje, F., Walsh, M. L., Ahmad, K., Ibrahim, V., Alrefai, A., Chen, J., & Chaikof, E. L. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122464 · Cited by 47
Oral peptide therapeutics for diabetes treatment: State-of-the-art and future perspectives
Ding, B., Zhu, Z., Guo, C., Li, J., Gan, Y., & Yu, M. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.02.019 · Cited by 46
“It has been reported that pegylation diminishes the immunogenicity and antigenicity of proteins 104,105 , thereby preventing clearance by the immune system.”
BackgroundOrganic Nanoplatforms for Iodinated Contrast Media in CT Imaging
Zhang, P., Ma, X., Guo, R., Ye, Z., Fu, H., Fu, N., Guo, Z., Zhang, J., & Zhang, J. (2021) · Molecules · doi:10.3390/molecules26237063 · Cited by 49
Hyldbakk, A., Hansen, T., Hak, S., & Borgos, S. E. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.016 · Cited by 44
Hlapisi, N., Songca, S. P., & Ajibade, P. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16101268 · Cited by 47
“The Food and Drug Administration (FDA) has authorized the application of this neutral, hydrophilic, and biocompatible polymer for biomedical and pharmaceutical purposes [176].”
BackgroundKorpusik, A. B., Tan, Y., Garrison, J. B., Tan, W., & Sumerlin, B. S. (2021) · Macromolecules · doi:10.1021/acs.macromol.1c01276 · Cited by 44
Polymeric Hydrogels for In Vitro 3D Ovarian Cancer Modeling
Braccini, S., Tacchini, C., Chiellini, E., & Puppi, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063265 · Cited by 49
“Thanks to its well-documented properties, such as high solubility in aqueous media, biocompatibility, and the ability to effectively hide from the host’s immune system, the polymer has received approval from FDA for use in pharmaceutical, cosmetic, and biomedical applications [256,257].”
BackgroundLipid-mediated ex vivo cell surface engineering for augmented cellular functionalities
Kim, S., & Kim, K. (2022) · Biomaterials Advances · doi:10.1016/j.bioadv.2022.213059 · Cited by 45
Understanding the relevance of protein corona in nanoparticle-based therapeutics and diagnostics
Chakraborty, D., Radhakrishnan, E. K., & Mukherjee, A. (2020) · RSC Advances · doi:10.1039/d0ra05241h · Cited by 45
The use of natural gums to produce nano-based hydrogels and films for topical application
Sari, M. H. M., Ferreira, L. M., & Cruz, L. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122166 · Cited by 46
Microencapsulation-based cell therapies
Marikar, S. N., El‐Osta, A., Johnston, A. P. R., Such, G. K., & Al‐Hasani, K. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04369-0 · Cited by 44
“Synthetic zwitterionic polymers, like polyoxazolines, are neutral in charge but are composed of both cationic and anionic groups promoting a high hydrophilicity which lends them the low non-specific interaction and non-immunogenic properties amongst many others [45, 48].”
BackgroundEljack, S., David, S., Faggad, A., Chourpa, I., & Allard-Vannier, É. (2022) · International Journal of Pharmaceutics X · doi:10.1016/j.ijpx.2022.100126 · Cited by 53
Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 46
“Increased understanding of these long-term responses will not only ensure patient safety but can also motivate the development of new materials [515,516].”
BackgroundJarak, I., Pereira‐Silva, M., Paiva‐Santos, A. C., Veiga, F., Cabral, H., & Figueiras, A. (2021) · Applied Materials Today · doi:10.1016/j.apmt.2021.101217 · Cited by 44
Applications of Extracellular Vesicles in Triple-Negative Breast Cancer
Bissonnette, F. S.-D., Khoury, R., Mediratta, K., El‐Sahli, S., Wang, L., & Lavoie, J. R. (2022) · Cancers · doi:10.3390/cancers14020451 · Cited by 44
Słyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Kamoun, E. A., Elsabahy, M., Elbadry, A. M. M., Abdelazim, E. B., Mohsen, A. A., Aleem, M. A., Gao, H., Eissa, N. G., Elghamry, I., & Salim, S. A. (2025) · ACS Omega · doi:10.1021/acsomega.4c10652 · Cited by 37
Zhang, Y., Lane, M. E., & Moore, D. J. (2020) · Polymers · doi:10.3390/polym12122907 · Cited by 37
Bloise, N., Okkeh, M., Restivo, E., Pina, C. D., & Visai, L. (2021) · Nanomaterials · doi:10.3390/nano11020289 · Cited by 42
Advances in nano-biomaterials and their applications in biomedicine
Patil‐Sen, Y. (2021) · Emerging Topics in Life Sciences · doi:10.1042/etls20200333 · Cited by 40
Patient-Specific Nanoparticle Targeting in Human Leukemia Blood
Ju, Y., Li, S., Tan, A. E. Q., Pilkington, E. H., Brannon, P. T., Plebanski, M., Cui, J., Caruso, F., Thurecht, K. J., Tam, C. S. L., et al. (2024) · ACS Nano · doi:10.1021/acsnano.4c09919 · Cited by 38
Self-citationHaider, M. S., Ahmad, T., Yang, M., Hu, C., Hahn, L., Stahlhut, P., Gröll, J., & Luxenhofer, R. (2021) · Gels · doi:10.3390/gels7030078 · Cited by 41
“However, the limited biodegradability [16–18] and more recently emerging, PEG immunogenicity [19] has remained the associated issues.”
BackgroundRecent Advances in Gelatin-Based Nanomedicine for Targeted Delivery of Anti-Cancer Drugs
Raza, F., Liu, S., Zafar, H., Kamal, Z., Zheng, B., Su, J., & Qiu, M. (2021) · Current Pharmaceutical Design · doi:10.2174/1381612827666211102100118 · Cited by 37
Jansman, M. M. T., Coll-Satue, C., Liu, X., Kempen, P. J., Andresen, T. L., Thulstrup, P. W., & Hosta‐Rigau, L. (2022) · Biomaterials Advances · doi:10.1016/j.msec.2022.112691 · Cited by 36
Huang, H., Huang, S., Wang, T.-H., Lin, T., Huang, N.-C., Shih, O., Jeng, U., Chu, C., & Chiang, W. (2022) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2022.120390 · Cited by 36
Inflammation-responsive nanoparticles suppress lymphatic clearance for prolonged arthritis therapy
Qin, X., Pan, L., Chen, T., Li, D., Lin, X., Li, G., Feng, C., Ye, W., Liang, W., Chen, J., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.11.005 · Cited by 35
Schneider, P. M., Zhang, H., Simić, L., Dai, Z., Schrörs, B., Akilli‐Öztürk, Ö., Jian, L., Durak, F., Schunke, J., Bolduan, V., et al. (2024) · Advanced Materials · doi:10.1002/adma.202404784 · Cited by 50
Step-growth polymerization by the RAFT process
Tanaka, J., Li, J., Clouthier, S. M., & You, W. (2023) · Chemical Communications · doi:10.1039/d3cc01087b · Cited by 35
Pillar[n]arene-based polymeric systems for biomedical applications
Zhou, L., Cao, S., Liu, C., Zhang, H., & Zhao, Y. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215260 · Cited by 35
Thomas, J., Thomas, S. P., & Stephen, R. (2024) · Food Packaging and Shelf Life · doi:10.1016/j.fpsl.2024.101373 · Cited by 34
Targeting nanoparticles to malignant tumors
Sharma, N., Bietar, K., & Stochaj, U. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188703 · Cited by 41
Honmane, S. M., Charde, M. S., Salunkhe, S. S., Choudhari, P. B., & Nangare, S. (2022) · OpenNano · doi:10.1016/j.onano.2022.100059 · Cited by 39
Boltman, T., Meyer, M., & Ekpo, O. E. (2023) · Cancers · doi:10.3390/cancers15133388 · Cited by 41
Gould, S., & Templin, M. V. (2023) · Toxicology Letters · doi:10.1016/j.toxlet.2023.07.011 · Cited by 38
Guo, H., & Mi, P. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1988 · Cited by 37
Ebadi, M., Buskaran, K., Saifullah, B., Hussein, M. Z., Fakurazi, S., & Pastorin, G. (2020) · Polymers · doi:10.3390/polym12112716 · Cited by 36
“have used nanoparticles coated with polyethylene glycol to deliver doxorubicin [25] or polyarabic acid for the delivery of anticancer drugs [26].”
MethodAdvances in Nano-Enabled Platforms for the Treatment of Depression
Mutingwende, F. P., Kondiah, P. P. D., Ubanako, P. N., Marimuthu, T., & Choonara, Y. E. (2021) · Polymers · doi:10.3390/polym13091431 · Cited by 40
Therapeutic peptides for chemotherapy: Trends and challenges for advanced delivery systems
Ilangala, A. B., Lechanteur, A., Fillet, M., & Piel, G. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.07.010 · Cited by 40
Hauptstein, N., Pouyan, P., Kehrein, J., Dirauf, M., Drießen, M. D., Raschig, M., Licha, K., Gottschaldt, M., Schubert, U. S., Haag, R., et al. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.1c00775 · Cited by 34
Gold NanoStars: Synthesis, Modification and Application
Lan, T., Cui, D., Liu, T., Yu, X., & Huang, M. (2023) · Nano Biomedicine and Engineering · doi:10.26599/nbe.2023.9290025 · Cited by 33
Liposomal Drug Delivery and Its Potential Impact on Cancer Research
Bhattacharya, S., Saindane, D., & Prajapati, B. G. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220418141640 · Cited by 37
Fawzy, M. P., Hassan, H. A. F. M., Sedky, N. K., Nafie, M. S., Youness, R. A., & Fahmy, S. A. (2024) · Nanoscale Advances · doi:10.1039/d4na00488d · Cited by 33
“83,84 PEGylated NPs acquire hydrophilicity and near-zero zeta potential, attributes that impede the attachment of opsonins, thereby evading recognition by the mononuclear phagocyte system and subsequent phagocytosis.”
Polymer Brush-Grafted Nanoparticles Preferentially Interact with Opsonins and Albumin
Leitner, N. S., Schroffenegger, M., & Reimhult, E. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01355 · Cited by 32
Opportunities for innovation: Building on the success of lipid nanoparticle vaccines
Huang, J. Y., Yuen, D., Mintern, J. D., & Johnston, A. P. R. (2021) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2021.101468 · Cited by 36
Leonardi, A. K., Medhi, R., Zhang, A., Düzen, N., Finlay, J. A., Clarke, J., Clare, A. S., & Ober, C. K. (2022) · Biomacromolecules · doi:10.1021/acs.biomac.1c01474 · Cited by 32
Polyacrylamide‐based hydrogel coatings improve biocompatibility of implanted pump devices
Chan, D. C., Maikawa, C. L., d’Aquino, A. I., Raghavan, S. S., Troxell, M. L., & Appel, E. A. (2023) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.37521 · Cited by 34
Noncovalent PEGylation of protein and peptide therapeutics
Andrianov, A. K. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1897 · Cited by 34
de Souza, J. R., Cardoso, L. M., de Toledo, P. T. A., Rahimnejad, M., Kito, L. T., Thim, G. P., Campos, T. M. B., Borges, A. L. S., & Bottino, M. C. (2024) · Journal of Biomedical Materials Research Part B: Applied Biomaterials · doi:10.1002/jbm.b.35406 · Cited by 30
Stem Cells and Hydrogels for Liver Tissue Engineering: Synergistic Cure for Liver Regeneration
Nadi, A., Moradi, L., Ai, J., & Asadpour, S. (2020) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10060-3 · Cited by 31
“bioconjugation, cell transplantation, stimulation, drug delivery, and regenerative medicine (Li et al. 2020; Thi et al. 2020).”
BackgroundChuzeville, L., Boury, F., Duday, D., Anand, R., Moretto, E., & Thomann, J. (2022) · Green Chemistry · doi:10.1039/d1gc03396d · Cited by 33
Thambi, T., Hong, J., Yoon, A. R., & Yun, C. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00469-y · Cited by 31
Anti-inflammation-based treatment of atherosclerosis using Gliclazide-loaded biomimetic nanoghosts
Karami, Z., Mehrzad, J., Akrami, M., & Hosseinkhani, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-41136-y · Cited by 35
Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions
Shahrivar, R. Y., Fakhr, Z. A., Abbasgholinejad, E., & Doroudian, M. (2023) · Advanced Therapeutics · doi:10.1002/adtp.202300275 · Cited by 32
Abrishami, A., Bahrami, A. R., Saljooghi, A. S., & Matin, M. M. (2024) · Nanoscale · doi:10.1039/d3nr06642h · Cited by 32
Taylor Dispersion Analysis to support lipid-nanoparticle formulations for mRNA vaccines
Malburet, C., Leclercq, L., Cotte, J., Thiebaud, J., Bazin, E., Garinot, M., & Cottet, H. (2022) · Gene Therapy · doi:10.1038/s41434-022-00370-1 · Cited by 31
Le, N. T. T., Trinh, B. T. D., Nguyen, D. H., Лам, Т. Д., Luu, C. H., & Thi, T. T. H. (2020) · Journal of Cluster Science · doi:10.1007/s10876-020-01823-6 · Cited by 29
Self-citationGierej, A., Geernaert, T., Vlierberghe, S. V., Dubruel, P., Hugo Thienpont, A., & Berghmans, F. (2021) · Materials · doi:10.3390/ma14081972 · Cited by 32
“PEG has been widely utilized in biomedical applications, such as bioconjugation, in which it is either directly conjugated with drugs or attached to the surface of drug-encapsulating nanomaterials (a technique known as PEGylation) [95], in drug delivery [96], in biosensing (e.”
BackgroundCancer Nanopharmaceuticals: Physicochemical Characterization and In Vitro/In Vivo Applications
Zielińska, A., Szalata, M., Gorczyński, A., Karczewski, J., Eder, P., Severino, P. B., Cabeda, J. M., Souto, E. B., & Słomski, R. (2021) · Cancers · doi:10.3390/cancers13081896 · Cited by 32
“A series of alternative, PEG-related compounds was recently reviewed [90,91] e.”
BackgroundAchievements and Bottlenecks of PEGylation in Nano-delivery Systems
Shen, R., & Yuan, H. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220929152644 · Cited by 30
Metadata
- Authors
- Hoang Thi, T. T., Pilkington, E. H., Nguyen, D. H., Lee, J. S., Park, K. D., & Truong, N. P.
- Affiliations
- Biomaterials and Nanotechnology Research Group, Faculty of Applied Sciences, Ton Duc Thang University, Ho Chi Minh City 758307, Vietnam
- Monash University (AU)
- Graduate University of Science and Technology (VN)
- Yale University (US)
- Ajou University (KR)
- Corresponding author
- Truong, Nghia P.
- ORCID
- Venue
- Polymers
- Publisher
- MDPI AG
- Published
- 2020-02-02
- Volume
- 12
- Issue
- 2
- Pages
- 298
- ISSN
- 2073-4360 (ISSN-L)
- PMC
- PMC7077443
- OpenAlex
- W3003603323
- Cited by
- 668
- References
- 79
- Citations by year
- 2026: 63 · 2025: 106 · 2024: 117 · 2023: 126 · 2022: 118 · 2021: 85 · 2020: 53
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Polymers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Monash University Research Portal (Monash University) (submittedVersion, cc-by)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Australian Research Council (DE180100076, DP200100231)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- polyethylene glycol, anti-PEG antibodies, PEGylation, PEG alternatives, drug delivery, bioconjugation, nanomedicine, blood circulation time, hypersensitivity, siRNA, microRNA, oligonucleotides, nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.